What was recalled
This page synthesizes the fish-oil-specific framework within the broader omega-3 sourcing landscape covered on the omega-3 EPA/DHA source comparison page. Marine fish oils dominate pre-formed EPA and DHA supplementation in commercial pet food. The fish accumulate EPA and DHA from dietary intake of microalgae through the marine food web; oil composition reflects the species' position in the food web and dietary marine biomass composition. Anchovy and sardine are short-lifecycle pelagic fish feeding directly on phytoplankton-derived microalgae; their oil reflects the high-EPA composition of the source microalgae. Salmon are predatory fish feeding on smaller fish; wild salmon oil reflects accumulated EPA and DHA from prey species, while farmed salmon oil reflects feed-formulation choices including increasing plant-feed substitution that reduces total omega-3. Tuna are long-lifecycle large predatory fish; tissue accumulation favors longer-chain DHA over shorter-chain EPA due to retroconversion in tuna metabolism. Krill are crustaceans feeding on phytoplankton; krill oil composition is similar to anchovy and sardine but in phospholipid-bound form.
Clinical applications of omega-3 supplementation in dogs and cats fall into roughly two categories by EPA versus DHA preference. Inflammation-modulation indications (atopic dermatitis, osteoarthritis, inflammatory bowel disease, chronic kidney disease with proteinuria) benefit from EPA-dominant supplementation because EPA is the substrate for prostaglandin E3 (anti-inflammatory) and resolvin E1/E2 (active resolution of inflammation). Cardiac applications (canine dilated cardiomyopathy, feline hypertrophic cardiomyopathy) benefit from EPA-dominant supplementation for anti-arrhythmic and anti-fibrotic effects. Structural and developmental indications (cognitive support, retinal development in growing pets, neural-tissue maintenance in senior pets) benefit from DHA-dominant supplementation due to structural incorporation into neural and retinal membrane phospholipids.
Why it was recalled
The structural controversy has three layers. Layer one — label transparency gap: standard commercial pet food labels disclose total omega-3 fatty acid percentage on Guaranteed Analysis without distinguishing ALA, EPA, and DHA. Brands using marine fish oil rarely disclose source species (anchovy versus salmon versus tuna versus mixed) or EPA:DHA breakdown. Veterinary therapeutic supplements (Welactin, Nordic Naturals Pet, ProMotion, Nutramax Dasuquin with MSM omega-3) do disclose EPA and DHA separately and identify source species. The transparency gap is structural across mainstream commercial pet food.
Layer two — clinical-indication mismatch: a pet owner managing canine atopic dermatitis benefits from EPA-dominant supplementation; a pet owner managing senior canine cognitive decline benefits from DHA-dominant supplementation. Standard commercial pet food cannot match the clinical indication without source-species and EPA:DHA disclosure. Some premium brands using salmon oil sourcing inadvertently provide DHA-dominant (or balanced) supplementation that fits cognitive and developmental indications better than inflammation-modulation indications. The current transparency gap means pet owners cannot select optimally for clinical indication based on the label alone.
Layer three — farmed-salmon omega-3 decline: farmed salmon represent the majority of global salmon production. Aquaculture feed formulation has shifted toward higher plant-feed inclusion (soybean meal, rapeseed oil, corn meal) over the past two decades to reduce reliance on fish-meal and fish-oil feed ingredients. The shift has reduced farmed salmon flesh omega-3 content by 30-50% over 2000-2020 in some studies. Pet food brands using "salmon oil" as a marketing differentiator may be sourcing from a substantially less omega-3-rich raw material than the marketing implies; the actual EPA and DHA delivery depends on source-fishery practices that are rarely disclosed.
Health risks for your pet
The health-risk profile is generally favorable at therapeutic dose; clinical adverse effects parallel the broader omega-3 supplementation framework. Mercury and PCB contamination warrant attention specifically for fish oil supplementation. Long-lifecycle large predatory fish (tuna, swordfish, shark, large salmon) accumulate methylmercury and persistent organic pollutants through the marine food web. Short-lifecycle small pelagic fish (anchovy, sardine, herring, mackerel) accumulate much less. Pet food brands using anchovy, sardine, herring, or menhaden as fish oil source provide better contamination profile than tuna oil sourcing. Independent assay testing (IFOS — International Fish Oil Standards) certifies low-contamination fish oils; some pet food brands and most veterinary therapeutic supplements use IFOS-certified sourcing.
Sustainability concerns are real for fish oil supply. Marine Stewardship Council (MSC) certifies sustainable fisheries; pet food brands using MSC-certified fish oil contribute less to fishery depletion than uncertified sourcing. The pet food industry historically used menhaden as primary fish oil source; menhaden fisheries face sustainability constraints. Anchovy and sardine sourcing varies by region; Peruvian and Chilean anchoveta fisheries are major suppliers with mixed sustainability records. Third-party certification transparency covers the certification framework in depth; MSC certification on fish oil is a transparency signal but does not address EPA:DHA composition independently.
What to do if you bought affected product
Pet owners can manage fish oil EPA:DHA selection through several practical approaches: (1) identify clinical indication first — inflammation-modulation (atopic dermatitis, osteoarthritis, cardiac, CKD) benefits from EPA-dominant; cognitive and developmental indications benefit from DHA-dominant; balanced supplementation suits general supplementation without specific indication; (2) request source-species and EPA:DHA disclosure from brand customer service; brands willing to disclose are signaling higher transparency; brands declining to disclose are signaling lower; (3) veterinary therapeutic supplements (Welactin, Nordic Naturals Pet, ProMotion, Nutramax Dasuquin with MSM omega-3) disclose EPA and DHA and identify source species; preferred for clinical indications over relying on diet-embedded fish oil; (4) prefer short-lifecycle small pelagic source species (anchovy, sardine, herring, mackerel, menhaden) over long-lifecycle large predatory species (tuna, swordfish, shark, large salmon) for contamination profile; IFOS certification is the relevant transparency signal; (5) monitor for rancidity in fish-oil-fortified pet food; PUFA oxidation post-open-bag is the structural concern; refrigerated supplements may be preferable to shelf-stable for high-PUFA products; (6) balance with vitamin E — omega-3 supplementation increases vitamin E requirement; veterinary therapeutic omega-3 supplements typically include vitamin E in the formulation.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate fish oil source species or EPA:DHA ratio per our published methodology, since brand-level transparency on these dimensions is rare and the clinical-indication match varies substantially by pet population. Future rubric extension under consideration: brands disclosing source species and EPA:DHA breakdown would receive favorable scoring weight; IFOS-certified or MSC-certified sourcing would receive scoring credit. Pet owners with clinical indications should select veterinary therapeutic supplements with disclosed composition rather than relying on diet-embedded fish oil for therapeutic dose; the diet provides baseline nutritional adequacy, the supplement provides clinical-indication dose. The transparency gap on EPA:DHA composition is structural across mainstream commercial pet food and will likely require AAFCO regulatory update to address.